News & Media

Press release
Medivir receives the International Diamond Prize for Excellence in Quality

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company has been awarded the International Diamond Prize for...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2019

July – September Financial summary Net turnover amounted to SEK 1.7 (3.0) million. The loss before interest, tax, depreciation and amortization...

Read more
Press release
Medivir reports last patient recruited to the phase Ia study of MIV-818 in liver cancer patients and initial dose determined for phase Ib

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) reports today that the ninth and final patient was recruited to the phase...

Read more
Press release
Medivir presents MIV-818 data at AACR-NCI-EORTC in Boston

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a poster entitled “MIV-818 stimulates an anti-tumor immune response in...

Read more
Press release
US National Cancer Institute initiates phase I study of treatment of head and neck cancer patients with Medivir’s birinapant and radiation therapy

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in a phase I...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2019

April – JuneSignificant events during the quarter Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The...

Read more
Press release
Selective effect signal on liver cancer tissue in phase Ia study with MIV-818

Stockholm, Sweden – Medivir AB (Nasdaq, Stockholm: MVIR) today announces the results of an analysis of data from the first six...

Read more
Press release
Medivir to present at the 2019 BIO International Convention

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in...

Read more
Press release
New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Read more
Press release
Medivir to present at the Redeye Pre-ASCO Seminar on May 28

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm....

Read more
Press release
New data from the phase I study of birinapant in combination with Keytruda® will be presented at the ASCO 2019

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Read more
Press release
Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that positive data from the investigator-initiated study evaluating the effects of...

Read more